InfiNano welcomes strategic partnerships with pharmaceutical companies, healthcare institutions, and investment partners to accelerate clinical translation and commercialization of breakthrough nanotherapeutics.
Contemporary drug/ medicine development faces three fundamental challenges limiting clinical efficacy:
Molecule-Centric Development Approach
Current pharmaceutical R&D prioritizes novel molecular entity discovery while inadequately addressing critical pharmacokinetic and biodistribution challenges. Therapeutic efficacy depends not solely on molecular mechanism, but critically on targeted delivery and bioavailability at disease sites.
Insufficient Spatial Resolution in Drug Delivery
Conventional systemic administration achieves therapeutic concentrations at organ/tissue level but fails to achieve precision at cellular and subcellular compartments where pathophysiological processes originate, resulting in suboptimal therapeutic indices.
High Attrition Rates in Clinical Translation
Promising molecular candidates frequently fail in clinical development due to unfavorable pharmacokinetic profiles, dose-limiting toxicities, and poor tissue penetration—not due to inadequate target engagement, but due to delivery system limitations preventing optimal biodistribution.
/ InfiNano Transforming Innovation into Real Life application.
/ InfiNano Transforming Innovation into Real Life application.
A targeted nano-actives delivery system employing lipid-based nanocarriers is a precision-engineered platform designed to transport functional active compounds to specific biological or cosmetic sites with enhanced selectivity and controlled release. Unlike drug-centric systems, nano-actives frameworks focus on delivering bioactive ingredients—such as antioxidants, peptides, botanical extracts, vitamins, or signaling modulators—while protecting them from degradation and improving penetration through physiological or epidermal barriers.
Overall, a lipid-based targeted nano-actives delivery system integrates selective targeting, protective encapsulation, and controlled release to substantially enhance the performance, stability, and precision of active compounds across therapeutic, cosmetic, and dermal applications.
- Non-specific biodistribution with high off-target exposure.
- Poor aqueous solubility limiting bioavailability.
- Dose-limiting systemic toxicities.
- Rapid clearance requiring frequent dosing.
- Broad therapeutic window requirements.
- Active targeting enabling cellular-level precision.
- Controlled-release kinetics optimizing therapeutic exposure.
- Enhanced solubilization of hydrophobic compounds.
- Reduced systemic toxicity through targeted accumulation.
- Superior therapeutic indices.
- Decreased treatment burden and healthcare costs.
Therapeutic Focus AreasTranslational Research Across Multiple Therapeutic Domains
Dermatological Applications
Therapeutic nanosystems for enhanced dermal/transdermal delivery in across skin conditions, dermatitis, inflammatory and cosmeceutical applications. Deeper absorption till subcutaneous level.
Advanced Wound Care & Trauma Management
Nano-engineered formulations accelerating tissue regeneration and hemostasis, radiation dermatitis, mucositis in complex wound environments.
Oncology
Accessible Precision Cancer Therapeutics Novel nanoparticle-mediated interventions combining targeted delivery with localized photothermal ablation for solid tumors.
Scientific Validation & InfrastructureRobust IP Portfolio and Clinical Development Capabilities
Intellectual Property
- US Patent granted for proprietary nanoformulation technology.
- Multiple patent applications filed (India, International).
- Strong freedom-to-operate position.
Scientific Leadership
- Led by Vigyan Ratna and Vigyan Shri Award-winning scientists.
- Collaborative research partnerships with premier institutions.
- Principal investigators from Tata Memorial Centre/ACTREC.
Manufacturing & Regulatory
- GMP-compliant manufacturing capabilities.
- Regulatory strategy guided by former FDA Joint Commissioner.
- Quality systems aligned with global regulatory requirements.
- FDA Approved, 350 Formulations Approved. HVAC Manufacturing.
